表紙
市場調査レポート

製薬会社、バイオテクノロジー企業、診断企業における資産購入提携条件・契約

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 136618
出版日 ページ情報 英文 929 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
製薬会社、バイオテクノロジー企業、診断企業における資産購入提携条件・契約 Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016
出版日: 2016年05月02日 ページ情報: 英文 929 Pages
概要

当レポートでは、医薬品関連企業における実際の資産購入契約文書をもとにケーススタディを交えながら取引概要をまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 資産購入取引動向

  • イントロダクション
  • 購入する資産の種類
  • 資産購入取引の動向
  • 資産購入提携取引に入る理由
  • ロイヤルティ資産購入取引
  • 資産購入取引における知的財産オークションハウスの役割
  • 将来動向

第3章 資産購入取引構造の概要

  • イントロダクション
  • 資産購入取引構成
  • 契約事例
  • ロイヤルティ資産購入契約の構成
  • ロイヤルティ資産購入契約書事例

第4章 主な製品・資産購入取引

  • イントロダクション
  • 契約額別上位の資産購入取引
  • 最も活発な資産購入取引企業
  • 大手製薬会社の資産購入取引活動

第5章 大手製薬会社の資産購入取引

  • イントロダクション
  • 資産購入取引の利用の仕方
  • 大手企業資産購入取引プロファイル

第6章 大手バイオテクノロジー企業の資産購入取引

第7章 資産購入契約ディレクトリ

  • イントロダクション
  • 企業名A-Z
  • 開発段階別
  • 治療分野別
  • 技術別

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2054

The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.

Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

  • Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations
  • Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit
  • Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
  • Technology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 1,000 asset purchase deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Asset Purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in Asset Purchase as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of Asset Purchase deals. The chapter includes numerous case studies to enable understanding of both pure Asset Purchase deals and multicomponent deals where Asset Purchase forms a part.

Chapter 4 provides a review of the leading Asset Purchase deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 most active Asset Purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of Asset Purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Asset Purchase deal.

The appendices to the report includes a comprehensive listing of all Asset Purchase deals announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in Asset Purchase dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about Asset Purchase alliances.

Key benefits

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016 provides the reader with the following key benefits:

  • In-depth understanding of asset purchase deal trends since 2010
  • Analysis of the structure of asset purchase agreements with numerous real life case studies
  • Comprehensive access to over 1,000 actual asset purchase deals entered into by the world's biopharma companies
  • Detailed access to actual asset purchase deals entered into by leading biopharma companies
  • Insight into the terms included in a asset purchase agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016 is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016 includes:

  • Trends in asset purchase dealmaking in the biopharma industry since 2010
  • Analysis of asset purchase deal structure
  • Case studies of real-life asset purchase deals
  • Access to over 1,000 asset purchase deal records
  • The leading asset purchase deals by value since 2010
  • Most active asset purchase dealmakers since 2010
  • The leading asset purchase partnering resources

In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive access to available records for over 1,000 asset purchase deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2016 provides the reader with the following key benefits:

  • In-depth understanding of asset purchase partnering deal trends since 2010
  • Insight into the terms included in an asset purchase agreement, together with real world clause examples
  • Identify leading asset purchase deals by value since 2010
  • Identify the most active asset purchase dealmakers since 2010
  • Full listing of asset purchase deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to over 1,000 asset purchase deals entered into by the world's biopharma companies, together with contract documents if available
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Asset Purchase dealmaking

  • 2.1. Introduction
  • 2.2. Types of assets purchased
  • 2.3. Trends in Asset Purchase deals since 2010
    • 2.3.1. Asset Purchase dealmaking by year, 2010 to 2016
    • 2.3.2. Asset Purchase dealmaking by phase of development, 2010 to 2016
    • 2.3.3. Asset Purchase dealmaking by industry sector, 2010 to 2016
    • 2.3.4. Asset Purchase dealmaking by therapy area, 2010 to 2016
    • 2.3.5. Asset Purchase dealmaking by technology type, 2010 to 2016
    • 2.3.6. Asset Purchase dealmaking by most active company, 2010 to 2016
  • 2.4. Reasons for entering into asset purchase partnering deals
    • 2.4.1. Business assets
    • 2.4.2. Product assets
    • 2.4.3. Royalty assets
    • 2.4.4. Technology assets
  • 2.5 The emergence of royalty asset purchase deals
    • 2.5.1. Primary players in royalty asset purchase deals
    • 2.5.3. The future of royalty asset purchase deals
  • 2.6. The role of IP auction houses in asset purchase deals
    • 2.6.1. Leading IP auction companies
  • 2.7. The future of asset purchase agreements

Chapter 3 - Overview of Asset Purchase deal structure

  • 3.1. Introduction
  • 3.2. Asset purchase agreement structure
  • 3.3. Example asset purchase agreements
    • 3.3.1. Case study 1: Product asset: QLT - Valeant Pharmaceuticals
    • 3.3.2. Case study 2: Business asset: Merck and Co - Bayer
  • 3.4. Anatomy of a royalty asset purchase agreement
  • 3.5. Example royalty asset purchase agreements
  • 3.5.1. Case study 3: Royalty asset: BioTime Acquisition Corporation- Geron Corporation

Chapter 4 - Leading Asset Purchase deals

  • 4.1. Introduction
  • 4.2. Top Asset Purchase deals by value

Chapter 5 - Top 50 most active Asset Purchase dealmakers

  • 5.1. Introduction
  • 5.2. Top 50 most active Asset Purchase dealmakers

Chapter 6 - Asset Purchase deals including contracts directory

  • 6.1. Introduction
  • 6.2. Asset Purchase deals with contracts 2010 to 2016

Appendices

  • Appendix 1 - Asset Purchase dealmaking by companies A-Z
  • Appendix 2 - Asset Purchase dealmaking by industry sector
  • Appendix 3 - Asset Purchase dealmaking by stage of development
  • Appendix 4 - Asset Purchase dealmaking by therapy area
  • Appendix 5 - Asset Purchase dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of assets purchased
  • Figure 2: Trends in Asset Purchase deal announcements, 2010 to 2016
  • Figure 3: Asset Purchase deals signed at each phase of development, 2010 to 2016
  • Figure 4: Asset Purchase deals by industry sector, 2010 to 2016
  • Figure 5: Asset Purchase deals by therapy area, 2010 to 2016
  • Figure 6: Asset Purchase deals by technology type, 2010 to 2016
  • Figure 7: Top 50 most active Asset Purchase dealmakers, 2010 to 2016
  • Figure 8: Leading royalty asset investors
  • Figure 9: Leading IP auction companies
  • Figure 10: Components of the asset purchase deal structure
  • Figure 11: Components of the royalty asset purchase deal structure
  • Figure 12: Top Asset Purchase deals by value 2010 to 2016
  • Figure 13: Most active Asset Purchase dealmakers 2010 to 2016
Back to Top